Key clinical point: Avoidance of severe cognitive impairment guided parent and physician choices more than any other late-life risk associated with cancer treatment.
Major finding: Parents were more likely to choose a treatment associated with no or mild neurocognitive impairment, compared with one that caused severe impairment (odds ratio, 2.83 for no impairment vs. severe impairment; P less than .001), in exchange for a 10% higher risk of treatment failure.
Study details: A discrete choice experiment survey to which 95 parents and 41 physicians responded at a single cancer treatment center.
Disclosures: Dr. Greenzang and colleagues’ study was funded by the National Institutes of Health and an Agency for Healthcare Research and Quality grant. The investigators declared no relevant financial disclosures.
Greenzang et al. Pediatrics. 2020;145(5):e20193552.